Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11563478 | 0.99 | OPRM1 (0.54) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL800612 | 0.87 | OPRM1 (0.48) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL780308 | 0.85 | NPFFR1 (0.49) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| Alcohol SCHEMBL7851452 | 0.84 | OPRM1 (0.48) | OPRM1SLC22A1ABCB1NPFFR1NPFFR2 | |
| SCHEMBL9148987 | 0.83 | NPFFR1 (0.61) | OPRM1NPFFR1NPFFR2OPRD1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11565432 | 0.82 | NPFFR1 (0.60) | OPRM1NPFFR1NPFFR2OPRD1SMN1; SMN2 | |
| SCHEMBL11565221 | 0.80 | NPFFR1 (0.47) | OPRM1NPFFR1NPFFR2OPRD1SMN1; SMN2 | |
| SCHEMBL17064124 | 0.79 | OPRM1 (0.60) | OPRM1SLC22A1ABCB1OPRD1SMN1; SMN2 | |
| SCHEMBL11564641 | 0.79 | NPFFR1 (0.53) | NPFFR1NPFFR2SMN1; SMN2 | |
| SCHEMBL11562772 | 0.79 | OPRM1 (0.54) | OPRM1SLC22A1ABCB1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616464-B1 | IMPROVED PROCESS FOR THE PREPARATION OF A PRECURSOR OF SUFENTANIL BASE | MALLINCKRODT LLC (US) | 2018-01-03 | — | — | EP | claimed |
| EP-2616464-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | Mallinckrodt LLC (US) | 2013-07-24 | — | — | EP | claimed |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | US | claimed |
| WO-2012037309-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | WO | claimed |
| EP-2616464-B1 | IMPROVED PROCESS FOR THE PREPARATION OF A PRECURSOR OF SUFENTANIL BASE | MALLINCKRODT LLC (US) | 2018-01-03 | — | — | EP | disclosed |
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946433-B2 | Process for the preparation of sufentanil base and related compounds | MALLINCKRODT LLC (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2455377-B1 | Synthesis of fentanyl analogs | HAMELN RDS GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2455377-B1 | Synthesis of fentanyl analogs | HAMELN RDS GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2616464-A2 | IMPROVED PROCESS FOR THE PREPARATION OF SUFENTANIL BASE AND RELATED COMPOUNDS | Mallinckrodt LLC (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2455377-A1 | Synthesis of fentanyl analogs | hameln rds gmbh (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2455377-A1 | Synthesis of fentanyl analogs | hameln rds gmbh (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | MALLINCKRODT, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | MALLINCKRODT, INC. | 2004-07-15 | — | — | US | disclosed |
| EP-1246801-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-0721452-B1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT INC (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2001040184-A2 | METHODS FOR THE SYNTHESES OF ALFENTANIL, SUFENTANIL AND REMIFENTANIL | MALLINCKRODT INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-0721452-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | Mallinckrodt Chemical, Inc. (US) | 1996-07-17 | — | — | EP | disclosed |
| US-5489689-A | CONDENSING A PIPERIDONE WITH A PRIMARY AMINE TO FORM A 4-AMINO-4-CARBOXYAMINOPIPERIDINE; HYDROLYSIS; CONDENSATION WITH A MESYLATE CONTAINING A PHENYL, THIENYL OR 4-ETHYL-4,5-DIHYDRO-5-OXO-1H-TETRAZPINE | MALLINCKRODT CHEMICAL, INC. (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995009152-A1 | PROCESS FOR THE PREPARATION OF SUFENTANIL DERIVATIVES BY CARBENE ADDITION/AMINOLYSIS OF 4-PIPERIDONE | MALLINCKRODT CHEMICAL, INC. (US) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149071-A1 | New methods for the synthesis of alfentanil, sufentanil, and remifentanil | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885SLC22A1 4474/4885ABCB1 2872/4885 |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | SNRPD1, SNRPD2, SNRPA1 | OPRM1 18/4885SLC22A1 2445/4885ABCB1 1242/4885 |
| US-20040138461-A1 | Methods for the syntheses of alfentanil sufentanil and remifentanil | HNMT, OPRM1, ALKBH3 | OPRM1 2/4885SLC22A1 4355/4885ABCB1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.